AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05609851 — intervention group
Intervention type: OTHER
Intervention: Short Physical Performance Batary
Description: The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function.
Study NCT05609851 — intervention group
Intervention type: OTHER
Intervention: Occupational Balance Self-Assessment
Description: The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value.
Study NCT05780008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat My ABCs
Description: The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home.
Study NCT06430242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele rehabilitation
Description: In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
Study NCT06430242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
Study NCT05229419 — intervention group
Intervention type: OTHER
Intervention: complete blood count
Description: complete blood count will be done for corrosive cases
Study NCT06050577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral Semaglutide/Rybelsus
Description: Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
Study NCT06050577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
Study NCT04368104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Darwish test (office hysteroscopic bubble suction and tubal peristalsis)
Description: Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
Study NCT05337150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Intervention
Description: For the first 12-weeks of the study, participants will complete weekly web modules in which they will learn cognitive-behavioral strategies to support lifestyle modification. Participants will also receive weekly phone coaching calls for the first 12-weeks of the study, and monthly coaching calls thereafter for the remainder of the 24-week study period.
Study NCT05337150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balanced Calorie Deficit Eating Plan
Description: Participants will be prescribed a calorie target between 1200 and 1800 depending upon baseline weight and personal preference. Participants will be asked to monitor their dietary intake using MyFitnessPal and to submit food logs weekly. Calorie reduction content will be based primarily on the Diabetes Prevention Program protocol and adapted from existing behavioral treatment protocols. Individuals will receive general guidelines on eating a healthy diet, including reducing saturated fat, processed foods, refined sugars, and refined carbohydrates, and increasing intake of lean proteins, whole grains, and fruits and vegetables, but will be encouraged to flexibly decide which areas of their diet to modify to reduce calorie intake.
Study NCT05337150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ad Libitum Whole Food Plant-Based Eating Plan
Description: Participants will be prescribed a whole food plant-based (WFPB) low-fat vegan diet promoting intake of fruits, vegetables, starches, legumes, and whole grains. Participants will be encouraged to avoid processed foods, refined oils, and animal products (meat, fish, eggs, and dairy products), and to minimize consumption of high-fat plant-based foods. An adapted traffic-light diet chart will outline foods to eat daily, limit, and avoid. Participants will be advised to eat until satiation and not restrict energy intake. Participants will be asked to consume 50 μg vitamin B12 (methylcobalamin) daily. WFPB nutrition counseling content will be based upon existing successful programs. Each week, participants will complete a simplified dietary self-monitoring food frequency questionnaire aligned to correspond with the traffic light diet chart.
Study NCT06042192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK-254RX
Description: Two TK-254RX per day to predetermined application site
Study NCT04833660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
Study NCT04833660 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
Study NCT04790539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Study NCT06791226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-AlF-FAPI PET/CT, 18F-FDG PET/CT
Description: Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for diagnosis and staging.
Study NCT06792422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)
Study NCT06394076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked sodium hyaluronate gel for injection containing lidocaine
Description: Cross-linked sodium hyaluronate gel for injection containing lidocaine
Study NCT06126406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
Study NCT06126406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study NCT06792422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)
Study NCT04777123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sitting position
Description: patients will be left seated for 2 minutes after subarachnoid injection
Study NCT06239285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brief Violence Intervention VR (BVI-VR)
Description: BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
Study NCT06239285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
Study NCT06508151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel
Description: Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
Study NCT06508151 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: neovaginoplasty and vaginal mold
Description: Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
Study NCT05932394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery
Description: Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered.
Study NCT05932394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the usual unit treatment
Description: CAM-ICU scale is administered to the Control group. No visual material is used.
Study NCT04968665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gait testing, functional MRI
Description: diagnostic tests including the gait testing and functional MRI
Study NCT05289492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS884448
Description: EOS884448 will be administered in arm A,B and C
Study NCT05289492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide will be administered in arm B and C
Study NCT05289492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered in arm C
Study NCT06490614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine in superficial cervical plexus block
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
Study NCT04928885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wits Workout Program
Description: 12 week, one hour per week multi-modal, interactive training.
Study NCT04928885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group that receives intervention after the study
Description: The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
Study NCT06032559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE
Description: MORE plus TAU
Study NCT06032559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMP
Description: SMP plus TAU
Study NCT06032559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU only
Study NCT04894838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Description: Distal gastric bypass, revisonal surgery after failed RYGB
Study NCT04989088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProComp5 Infiniti System w/BioGraph Infiniti Software
Description: Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
Study NCT04989088 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ProComp5 Infiniti System w/recorded videos
Description: Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
Study NCT06505421 — intervention group
Intervention type: BEHAVIORAL
Intervention: Resistance training
Description: Eccentric resistance training and tradional resistance training
Study NCT05812196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
Study NCT05812196 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Verified COVID-19 infection.
Study NCT05056545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 Intervention
Description: C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW.
Study NCT06786741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AER for Stronger Communities
Description: 3 week rapid intervention aimed at reducing stress.
Study NCT06786741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 week short video program (control)
Study NCT06792318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET-CT
Description: FAPI PET-CT imaging protocol:~Single dose 68Ga/18F-FAPI (2 MBq/kg)~Two imaging sessions:~First: 10 and 30 minutes post-injection Second: 60 and 80 minutes post-injection Ultra-low dose CT for attenuation correction and anatomical localization
Study NCT06153069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course regimen
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Study NCT06153069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard regimen
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, >70kg 2000mg daily; ethambutol ≤50kg 750mg daily, >50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, >50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Study NCT06792370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (for children with MAM)
Description: Each child with MAM will be supplemented with RUTF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks.
Study NCT06792370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use supplementary food
Description: Each child with MAM will be supplemented with RUSF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery
Study NCT06792370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food - Reduced dose 1
Description: Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.